Successful treatment has been shown both in a transgenic mouse model of SMA and in human clinical trials, as evidenced by significant increases in full-length SMN2 pre-mRNA and greater levels of SMN protein in MNs [72,73]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.